Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. The firm is focused on developing and commercializing therapies for the treatment of chronic respiratory diseases with unmet medical needs. Ohtuvayre (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD) that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. The firm has evaluated nebulized Ohtuvayre in its Phase III clinical program ENHANCE (Ensifentrine as an Inhaled Nebulized COPD therapy) for COPD maintenance treatment. The company has developed formulations of ensifentrine for the three inhalation devices: nebulizer, dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). Ensifentrine has potential in other respiratory diseases such as non-cystic fibrosis bronchiectasis. The firm's subsidiaries include Verona Pharma, Inc. and Verona Pharma Ireland Limited.
Follow-Up Questions
Verona Pharma PLC 的 CEO 是誰？
Dr. David Zaccardelli 是 Verona Pharma PLC 的 President，自 2020 加入公司。
VRNA 股票的價格表現如何？
VRNA 的當前價格為 $106.91，在上個交易日 decreased 了 0%。
Verona Pharma PLC 的主要業務主題或行業是什麼？
Verona Pharma PLC 屬於 Pharmaceuticals 行業，該板塊是 Health Care
